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Chronic renal disease (CRD) associated with cardiovascular disease (CVD) and/or type 2 diabetes (T2D) 
is a significant problem in Aboriginal Australians. Whole exome sequencing data (N = 72) showed 
enrichment for ClinVar pathogenic variants in gene sets/pathways linking lipoprotein, lipid and glucose 
metabolism. The top Ingenuity Pathway Analysis canonical pathways were Farsenoid X Receptor and 
Retinoid Receptor (FXR/RXR; (P = 1.86 × 10−7), Liver X Receptor and Retinoid Receptor (LXR/RXR; 
P = 2.88 × 10−6), and atherosclerosis signalling (P = 3.80 × 10−6). Top pathways/processes identified 
using Enrichr included: Reactome 2016 chylomicron-mediated lipid transport (P = 3.55 × 10−7); Wiki 
2016 statin (P = 8.29 × 10−8); GO Biological Processes 2017 chylomicron remodelling (P = 1.92 × 10−8). 
ClinVar arylsulfatase A pseudodeficiency (ARSA-PD) pathogenic variants were common, including the 
missense variant c.511 G > A (p.Asp171Asn; rs74315466; frequency 0.44) only reported in Polynesians. 
This variant is in cis with known ARSA-PD 3′ regulatory c.*96 A > G (rs6151429; frequency 0.47) and 
missense c.1055 A > G (p.Asn352Ser; rs2071421; frequency 0.47) variants. These latter two variants 
are associated with T2D (risk haplotype GG; odds ratio 2.67; 95% CI 2.32–3.08; P = 2.43 × 10−4) in 
genome-wide association data (N = 402), but are more strongly associated with quantitative traits 
(DBP, SBP, ACR, eGFR) for hypertension and renal function in non-diabetic than diabetic subgroups. 
Traits associated with CVD, CRD and T2D in Aboriginal Australians provide novel insight into function of 
ARSA-PD variants.
Chronic (CRD) and end stage (ESRD) renal disease associated with cardiovascular disease (CVD) and/or type 
2 diabetes (T2D) are major health problems in Aboriginal Australians1,2. Around 10% of new cases of ESRD 
are Aboriginal Australians, despite making up only 2.5% of the population3. Aboriginal Australians pres-
ent with ESRD at a younger age, with 70% of Indigenous cases occurring at <60 years compared to 20% for 
non-Indigenous Australians3. The most common causes of ESRD are T2D, glomerulonephritis, and hypertension 
(HTN)3. A body mass index (BMI) > 22 kg/m2 is a significant risk factor for T2D in Aboriginal Australians2. BMI 
is also a risk factor for ESRD independently of diabetes4.
Genome-wide association studies (GWAS) have been used successfully in large-scale cohorts to identify com-
mon genetic variants associated with BMI and T2D5, and for quantitative traits (QT) related to CVD/HTN or 
CRD/ESRD6,7. We undertook the first GWAS looking for common variants associated with BMI and T2D in 
Aboriginal Australians8, and found evidence for genes/pathways in common with genetic risk factors in other 
ethnicities. This included top hits for BMI 5′ of NTRK2, the type 2 neurotrophic tyrosine kinase receptor for 
brain-derived neurotrophic factor that regulates energy balance downstream of melanocortin-4 receptor, and for 
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T2D 5′ of BCL9 that, along with TCFL2, promotes beta-catenin’s transcriptional activity in the WNT signalling 
pathway. However, our study was not well-powered to provide definitive support for other hits that occurred 
genome-wide, and we did not look at possible roles of known functional variants, including rare variants, that 
may contribute to genetic risk for T2D, HTN/CVD or CRD/ESRD. Cumulative evidence highlights the contribu-
tion of less common or rare functional variants to complex diseases9–12, particularly in family-based analyses11,13. 
ClinVar is a public archive that catalogues the relationships between putative functional variants and human dis-
ease phenotypes14. Here we use whole exome sequencing (WES) to identify putative functional variants that may 
contribute to genetic risk for CRD/ESRD associated with CVD/HTN and/or T2D in this Australian Aboriginal 
population. We find enrichment for genes carrying ClinVar functional variants in gene sets/pathways that link 
bile acid regulation with lipoprotein, lipid and glucose metabolism. In addition, functional variants causing 
arylsulfatase A pseudodeficiency (ARSA-PD) are common in this population, are associated with T2D, and more 
strongly with QT for CVD/HTN and CRD/ESRD in non-diabetic individuals.
Results
Identifying functional variants using WES. Our initial focus was to analyse WES data from the 72 indi-
viduals (see methods) to identify putative functional variants per se that would provide an important popu-
lation-specific resource for clinical diagnosis of rare disease variants in the Aboriginal population15,16. Firstly, 
we compared all variants called in our WES data with functional disease-associated variants in ClinVar14. 
Supplementary Table S1 shows all ClinVar variants designated as pathogenic, likely pathogenic, or a risk factor in 
at least one study, with variant frequencies compared to Max-all. These variants ranged from deleterious variants 
of high burden that have previously been recorded as pathogenic for rare genetic disorders, to those contributing 
to quantitative and/or more complex phenotypes such as the cardiovascular and renal disease phenotypes of 
specific interest to this study (cf. below). Of interest, individuals were observed (summarised Table 1; presented 
in full in Supplementary Table S1) who were heterozygous for putative high burden genetic variants/disorders 
previously identified as autosomal dominant, while individuals homozygous for high burden variants were also 
observed for genetic disorders previously reported as autosomal recessive. Some of these may be of lower burden 
and could represent undiagnosed cases, while others may already be associated with conflicting interpretations 
of pathogenicity recorded in ClinVar. However, since none of the participants in the study presented with severe 
rare genetic disorders, the observed genotype frequencies for variants in this Aboriginal Australian population 
may also call into question the pathogenicity status of some that are recorded as high burden pathogenic variants 
in ClinVar. Clinically accredited sequence analysis will be required to determine the potential impact of these var-
iants in Aboriginal Australians presenting with rare genetic disorders. The de-identified research sequence data 
obtained here has been made available (see methods for details of data access) as a unique population frequency 
baseline for clinical diagnosis of rare disease variants in the Aboriginal population15,16.
Secondly, since there may be novel deleterious variants in the Australian Aboriginal population not present, 
or at very low frequency, in ClinVar or other public domain databases, we assigned CADD17 values to all variants 
called in the WES data and filtered for genes carrying potential deleterious variants. The top 5% of putative del-
eterious variants had scaled CADD scores ≥ 15.91, which aligns with the median value for all possible canonical 
splice site changes and non-synonymous variants in the human genome that has been suggested as a potential 
cut-off for pathogenicity in population-based studies17. The top 10% had scaled CADD scores ≥12.97. Those 
present (N = 352) at variant allele frequencies >0.2 in the study population, but with Max-all <0.1, are presented 
in Supplementary Table S2. Of these, 82 (listed as Vaf = −1) were not found in the databases used to determine 
Max-all, and 27 (listed as Vaf = 0) had Max-all <0.001.
Enrichment for ClinVar functional variants regulating lipoprotein, lipid and glucose metab-
olism. Using Enrichr18 (Supplementary Table S3) and IPA (Fig. 1) we looked for enrichment of gene sets 
and pathways in 72 genes containing 81 ClinVar pathogenic variants of lower burden than those definitively 
known to cause severe congenital genetic disorders (e.g. as discussed above in relation to Table 1). In addition 
to a general enrichment for genes involved in human metabolism as compared to the Reactome 2016 (adjusted 
P = 1.25 × 10−6) and KEGG 2016 (adjusted P = 1.43 × 10−4) databases, there was consistent evidence across 
all databases for enrichment of genes involved in lipid, lipoprotein and retinoid metabolism and transport 
(Supplementary Table S3). This was also concordant with the top canonical pathways for Farsenoid X Receptor 
and Retinoid Receptor (FXR/RXR), Liver X Receptor and Retinoid Receptor (LXR/RXR), and atherosclerosis 
signalling, identified using IPA (Fig. 1A). Network analysis in IPA (Fig. 1B) summarises how these genes interact. 
There was no significant enrichment for gene sets or pathways for the 136 genes carrying the top 5% of variants 
with scaled CADD score ≥ 15.91 and variant allele frequencies >0.2 in our study and Max-all <0.1. It is of note, 
nevertheless, that not all variants identified as pathogenic in ClinVar are robust to this stringent scaled CADD 
score cut-off (Supplementary Table S1). Lowering the threshold to look at the 301 genes carrying the top 10% of 
variants with scaled CADD score ≥ 12.97 and with variant allele frequencies >0.2 in our study and Max-all <0.1 
(Supplementary Table S2) showed significant enrichment for genes (DPH3, DRD2, LIF, OSM, RHBDF2; variant 
allele frequencies 0.236 to 0.806; Max-all <0.088; CADD-scaled 13.08 to 22.3) in the GO Biological Process 1917b 
database for negative regulation of adiponectin secretion (Enrichr nominal P = 5.4 × 10−6, adjusted P = 0.019). 
No other gene sets were robust to adjusted P < 0.05 in Enrichr or in IPA canonical pathway analysis (data not 
shown).
ARSA-PD variants in the study population. Amongst the pathogenic ClinVar variants present at high 
frequency in this Australian Aboriginal population was the ARSA missense variant c.511 G > A (p.Asp171Asn; 
rs74315466; causal allele frequency 0.44; Supplementary Table S1) reported as pathogenic for ARSA-PD 
in ClinVar. This variant (present in 1000 G at frequency 0.0049 in Indian Teluga from UK, and at 0.0156 in 
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Punjabi from Lahore) had only been previously reported19 as an unpublished observation in a Polynesian pop-
ulation in cis with a well-known ARSA-PD 3′ regulatory variant c.*96 A > G (rs6151429) which is also pres-
ent at a high frequency (0.47; Table 2) in our population compared to other ethnicities. These two variants are 
in strong linkage disequilibrium (LD; r2 = 0.88) with each other in our WES data. A second missense variant 
c.1055 A > G (p.Asn352Ser; rs2071421; traditionally named Asn350Ser) also occurred in cis with the PD-allele 
at rs6151429 (r2 = 1) in our WES data, consistent with the hypothesis that this 3′ polyadenylation regulatory 
variant c.*96 A > G arose on the background of the more ancient c.1055 A > G variant before the emergence of 
modern Homo sapiens from Africa20. Table 2 provides allele frequencies for the 2 well known ARSA-PD variants, 
rs6151429 and rs2071421, in our study compared against different ethnicities in the public domain databases.
The absence of the ARSA missense variant c.511 G > A (p.Asp171Asn; rs74315466) from ExAC, which con-
tains multiple ethnicities including African/African American (AFR), Latino (AMR), East Asian (EAS), Finnish 
(FIN), Non-Finnish European (NFE), and South Asian (SAS), suggests that this variant may be unique to Aboriginal 
Australians and Polynesian/Indian ethnicities, where it has arisen on the background of the classical ARSA-PD 
alleles of both the 3′ regulatory c.*96 A > G (rs6151429) and the c.1055 A > G (p.Asn352Ser; rs2071421) variants. 
This is also consistent with data from the first whole genome sequence of an Aboriginal Australian21 where the 
individual sequenced was homozygous for the PD-associated variant alleles at all 3 SNPs (rs6151429, rs2071421, 
rs74315466; data available at http://www.cbs.dtu.dk/public/aboriginal/genotyping/AusAboriginal/?C=S;O=A).
Chrom Gene SNP ID cDNA Protein
Genotype Freq
MoI Clinvar disease name/Phenotype
Hom 
Ref Het
Hom 
Var
Dominant disorders:
chr3 SCN5A rs199473118 rs1805124
c.1535 C > T 
c.1673A > G p.Thr512Ile p.His558Arg 54 15 3 AD Progressive familial heart block type 1 A (haplotype)
chr4 DSPP rs36094464 c.202 A > T p.Arg68Trp 67 5 0 AD Dentinogenesis imperfecta-Shield’s type II
chr6 HFE rs1800562 c.845 G > A p.Cys282Tyr 66 6 0 AD Porphyria cutanea tarda; Porphyria variegata
chr9 COL5A1 rs61735045 c.1588 G > A p.Gly530Ser 65 7 0 AD Ehlers-Danlos syndrome, classic_type
chr10 LDB3 rs145983824 c.1823C > T p.Pro608Leu 65 7 0 AD Familial hypertrophic cardiomyopathy 24
chr10 ZFYVE27 rs35077384 c.572 G > T p.Gly191Val 59 13 0 AD Spastic paraplegia 33, autosomal dominant
chr11 TYR rs1126809 c.1205 G > A p.Arg402Gln 63 9 0 CH; DG Oculocutaneous albinism 1/1B (CH); Waardenburg syndrome 2 and ocular albinism, digenic
chr11 ROM1 rs527236104 c.331dupG p.Leu114Alafs 63 8 1 DG Retinitis pigmentosa 7, digenic with RDS
chrX OFD1 rs398122866 c.688_705del18 p.Ile230_Lys235del 41 2 0 XLD Oral-facial-digital syndrome
Recessive disorders:
chr1 FMO3 rs2266782 c.472 G > A p.Glu158Lys 14 23 35 AR Trimethylaminuria
chr1 GNPAT rs11558492 c.1556 A > G p.Asp519Gly 39 27 6 AR Rhizomelic chondrodysplasia punctata 2
chr9 ADAMTS13 rs2301612 c.1342 C > G p.Gln448Glu 16 37 19 AR Upshaw-Schulman syndrome
chr4 KLKB1 rs3733402 c.428 G > A p.Ser143Asn 32 29 11 AR Prekallikrein deficiency
chr7 CFTR rs727504486 c.1210-12_1210-6T [5] NA 26 29 8 AR Absence vas deferens; Cystic_fibrosis
chr18 FECH rs2272783 c.315-48 T > C NA 42 26 4 AR Erythropoietic protoporphyria; Erythema
chr17 GAA rs1800309 c.2065 G > A p.Glu689Lys 46 21 5 AR Acid alpha-glucosidase, allele 4
chr5 IL7R rs1494558 c.197 T > C p.Ile66Thr 23 35 14 AR Severe combined immunodeficiency
chr5 RARS rs139644798 c.1367 C > T p.Ser456Leu 62 9 1 AR Leukodystrophy, hypomyelinating, 9
chr6 ESR1 rs6929137 c.1810G > A p.Val604Ile 33 30 9 AR Estrogen resistance
chr7 ATP6V0A4 rs3807153 c.1739T > C p.Met580Thr 40 26 6 AR Renal tubular acidosis, distal
chr12 ACADS rs1799958 c.625 G > A p.Gly209Ser 21 38 13 AR Deficiency of butyryl-CoA dehydrogenase
chr14 RPGRIP1 rs10151259 c.1639G > T p.Ala547Ser 24 32 16 AR Cone-rod dystrophy 13
Chr19 GCDH rs8012 c.1250 A > G p.Gln417Arg 9 30 33 AR Glutaric aciduria, type_1
chr19 GCDH rs9384 c.*288 G > T NA 14 28 30 AR Glutaric aciduria, type_1
chr19 MAG rs2301600 c.399 C > G p.Ser133Arg 49 22 1 AR Spastic paraplegia 75
Table 1. Summary of genotype frequencies in the Aboriginal Australian study population for putative high 
burden pathogenic variants. Complete data are provided in Supplementary Table S1. Summary data are 
provided here for variants in genes for which severe genetic disorders with autosomal (AD) or X-linked 
(XLD) dominant (where ≥4 heterozygotes were observed) or autosomal recessive (where ≥1 homozygote was 
observed) inheritance are reported (OMIM). Note for the one XLD variant at OFD1 the genotype frequencies 
given are for females; there were 27 males carrying the wildtype allele. Chrom = chromosome; SNP ID - rs 
ID as in DbSNP; cDNA = change caused by variant at cDNA level; Protein = change caused by variant at 
protein level; Genotype Freq = genotype frequencies for homozyzygous reference allele, heterozygotes, and 
homozygous variant allele; MoI = mode of inheritance (AD = autosomal dominant; XLD = X-linked dominant; 
AR = autosomal recessive; CH = compound heterozygotes; DG = digenic); ClinVar disease name = disease for 
which ClinVar records the pathogenicity assignment indicated.
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Figure 1. Results of canonical pathway and network analyses for 111 genes carrying 125 ClinVar functional 
variants. (A) Top canonical pathways analysed using QIAGEN’s Ingenuity Pathway Analysis (IPA; QIAGEN 
Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis)52 are shown along with 
nominal and adjusted p-values, and genes within our dataset involved in the listed pathways. (B) Plot showing 
the network of interconnected genes identified by Network Analysis undertaken using IPA. Genes with no 
previously documented interactions were removed from the diagram. The network contains 29 (40%) of the 
genes carrying ClinVar variants selected for pathway analysis, 16 of which (annotated in orange) are members 
of the top canonical pathways listed in (A) and/or enriched gene sets (Supplementary Table S3) involved in 
functions related to CVD.
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ARSA-PD variants associated with T2D. Arylsulfatase A (cerebroside-3-sulfate 3-sulfohydrolase; EC 
3.1.6.8) is a lysosomal enzyme that plays a role in catalysing the degradation of sulfatides, a subgroup of gly-
cosphingolipids important in diabetes22. Since both rs6151429 and rs2071421 were present on the Illumina 
2.5 M Duo beadchip used in our GWAS of 402 post-QC individuals8, we re-interrogated the data to determine 
whether these ARSA-PD variants were associated with T2D in this Aboriginal population. In this larger dataset, 
these two variants were in complete LD (r2 = 1) in 78 unrelated individuals of pure Martu ancestry, and in very 
strong LD (r2 = 0.99) in 146 unrelated individuals in this Aboriginal/Caucasian admixed population8. Linear 
Mixed Model analysis of 89 T2D cases ≥ 20 years old in the family-based dataset of 391 GWAS individuals8 
showed association with both rs2071421 (P = 5.49 × 10−4) and rs6151429 (P = 8.90 × 10−4) (data not shown). 
Logistic regression analysis of these 89 cases compared to 109 unaffected adults (≥20 years old) (Supplementary 
Table 3A) under an additive model concurred with data from the original GWAS, with the top associations at 
rs2071421 (odds ratio risk G allele = 2.73; 95% confidence interval 1.62–4.60; P = 1.54 × 10−4), rs6151429 (odds 
ratio risk G allele = 2.67; 95% confidence interval 1.58–4.52; P = 2.43 × 10−4) and other SNPs in complete LD 
with rs6151429. Analysis under dominant (rs2071421 odds ratio risk G allele = 3.41; 95% confidence interval 
1.65–7.04; P = 8.96 × 10−4) or recessive (rs2071421 odds ratio risk G allele = 3.421; 95% confidence interval 
1.37–8.53.60; P = 8.23 × 10−3) models provided higher odds ratios but larger variance and reduced significance. 
Association with T2D under an additive model is consistent with previous work demonstrating that individuals 
heterozygous for ARSA-PD variants have intermediate ARSA enzyme activity23.
Haplotype association analysis (Supplementary Table S4) of phased haplotypes across the 6 ARSA variants at 
the peak of the association demonstrated that T2D risk is associated with the haplotype AAGGAA (odds ratio 
2.67; P = 3.21 × 10−4) that carries G alleles at rs2071421 and rs6151429 previously associated with ARSA PD. 
Protection was associated with the haplotype GGAAGG (odds ratio 0.468; P = 2.77 × 10−3). In a sliding win-
dow analysis of pairwise haplotypes across the 6 SNPs (Supplementary Table S4) the peak risk haplotype (GA; 
odds ratio 2.91; P = 7.61 × 10−5) was observed across SNPs rs2071421 and rs6151419, raising the possibility that 
the more 5′ ARSA missense variant c.511 G > A (p.Asp171Asn; rs74315466) that lies distal to rs6151419 could 
contribute to the association. However, while conditioning on rs2071421 or rs6151429 removes significance at 
all other SNPs, conditioning on rs6151419 retains residual signals at both rs2071421 and rs6151429 (Table 3B). 
Hence, it seems likely that the association is fully accounted for by the two known ARSA-PD variants rs2071421 
and rs6151429.
ARSA-PD variants associated with HTN- and CRD-related quantitative traits. Serum sulfati-
des are also a biomarker for CVD, particularly in the context of ESRD24. We therefore looked for associations 
between ARSA-PD genotypes and quantitative traits (QT) associated with HTN (DBP; SBP) and renal function 
(ACR; eGFR). We also looked at associations with HbA1c used to monitor diabetes risk, and BMI as a risk fac-
tor for T2D. Since the ARSA-PD 3′ regulatory variant c.*96 A > G (rs6151429) has been shown experimentally 
to be the etiological variant for low ARSA activity associated with pseudodeficiency25, and the three variants 
rs6151429, rs2071421 and rs74315466 are in almost complete LD in our population, all associations with QT 
data are presented relative to rs6151429 genotypes. The 48 adults analysed by WES were selected for extremes 
of eGFR with/without T2D (Supplementary Table S5). We therefore looked initially for associations between 
rs6151429 genotypes and QT in this sample. DBP (Mean difference −10.7; 95% CI −18.56 to −2.836; P = 0.012), 
SBP (Mean difference −19.33; 95% CI −19.33 to −0.88; P = 0.042) and eGFR (Mean difference 32.99; 95% CI 
4.55 to 61.44; P = 0.027) were significantly associated with rs6151429 genotypes (Fig. 2). In each case the direc-
tion of differences is as expected, with the ARSA-PD GG genotype (i.e. homozygous for PD deficiency) asso-
ciated with at risk higher DBP and SBP, and lower eGFR. ACR was not significantly associated with rs6151429 
SNP Population
Variant 
Allele Count
2 N Total 
Allele Count
N Homozygotes for 
variant allele
Variant Allele 
Frequency
rs6151429; c.*96 A > G
Aboriginal 
Australia WD 68 144 14 0.472
AFR 5 1322 0 0.004
AMR 28 694 0 0.040
EAS 18 1008 1 0.018
EUR 82 1006 3 0.082
SAS 117 978 7 0.120
rs2071421; c.1055 A > G p.Asn352Ser
Aboriginal 
Australia WD 68 144 14 0.472
AFR 499 1322 104 0.377
AMR 175 694 31 0.252
EAS 161 1008 9 0.160
EUR 140 1006 12 0.140
SAS 151 978 11 0.154
Table 2. Population frequencies for ARSA-PD variants rs6151429 and rs2071421. Frequencies for Australian 
Aboriginals (WD = Western Desert, this study) are compared to different ethnicities in the 1000 Genomes 
project, including African/African American (AFR), Latino (AMR), East Asian (EAS), European (EUR), and 
South Asian (SAS).
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genotypes in the total WES adult (N = 48) sample. Of note, associations between rs6151429 genotypes and DBP 
(Mean difference −20.75; 95% CI −31.28 to −10.22; P = 0.001), SBP (Mean difference −27.88; 95% CI −51.57 to 
−4.19; P = 0.029), ACR (Median difference −83.4; P = 0.054) and eGFR (Mean difference 49.95; 95% CI 24.83 to 
75.07; P = 0.0005) were evident in the non-diabetic group but not the group with T2D (Fig. 2). Notably, HbA1c 
(Supplementary Fig. S2) and BMI (Supplementary Fig. S3) were not associated with rs6151429 genotypes, with 
or without stratification for T2D. These data suggest that the ARSA PD allele is acting directly on CVD and CRD, 
rather than as an indirect effect of its association with T2D as observed in the GWAS data. Conversely, the associ-
ation with T2D in the GWAS dataset may be due to correlation with CVD- and CRD-related traits.
Since rs6151429 was genotyped in all individuals used in the GWAS, we also examined associations with HTN 
(DBP, SBP) and CRD (ACR, eGFR) QT, as well as BMI and HbA1c, in this larger data set. Figure 3A,B showing 
DBP and SBP by age indicate that values only exceed clinical thresholds for HTN in adulthood. Associations 
between ARSA-PD genotypes and QT were therefore restricted to individuals aged ≥ 20 years. Significant asso-
ciations between rs6151429 genotype and DBP (Mean difference −5.63; 95% CI −10.34 to −0.92; P = 0.02) or 
SBP (Mean difference −16.6; 95% CI −26.49 to −6.72; P = 0.002) observed in the full dataset (Fig. 3C,D) were 
not evident following stratification by T2D (Fig. 3E,F). Maximum between group differences were observed when 
each T2D group was compared with the non-T2D group carrying the protective non-ARSA-PD allele, suggest-
ing that T2D disease was neutralising any protection afforded by genotypes heterozygous or homozygous for 
the non-PD allele. As for DBP and SBP, ACR and eGFR only exceed clinical thresholds for CRD in adulthood 
(Fig. 4A,B). The CRD-related trait ACR was significantly associated with rs6151429 genotype in the total group 
(Fig. 4C). Significance between genotypes and ACR were not evident once stratified by T2D (Fig. 4E), with max-
imum differences in ACR levels again observed when comparing the two T2D groups with the non-T2D group 
carrying the protective non-ARSA-PD allele. No significant associations between eGFR and rs6151429 genotype 
were observed in this larger dataset (Fig. 4D,F), nor with HbA1c (Supplementary Fig. S1) or BMI (Supplementary 
Fig. S2). Absence of evidence for any direct association between rs6151429 genotype and HbA1c lends weight to 
the suggestion that the functional association related to CVD/HTN and CRD is direct, and not indirectly through 
association with T2D.
Discussion
Few studies have used genome-wide analyses of Australian Aboriginal-ancestry populations to identify var-
iants contributing to high rates of CVD, CRD/ESRD and T2D. Amongst such variants we expect to observe 
some that are Australian Aboriginal-specific, or at higher frequency in this population, as has been observed, for 
example, for kidney disease26 and blood pressure27 in African-ancestry populations. In a family-based study, it 
was also likely that multiple rare variants might contribute to these phenotypes, as recently observed for blood 
pressure in families from the Cleveland family Study13. Using WES analysis of family members with extreme 
phenotypes we showed enrichment for genes carrying ClinVar functional variants in gene sets/pathways that 
link bile acid regulation with lipoprotein, lipid and glucose metabolism. Notable amongst ClinVar functional 
variants contributing to enriched gene sets/pathways, and occurring at high frequency, was APOE rs429358 
(c.388 T > C; p.Cys130Arg; frequency 0.326; also referred to as ApoE4, epsilon 4 or Cys112Arg) which is associ-
ated with familial_type_3_hyperlipoproteinemia28. The Max-all frequency of 0.273 in our database comparison 
(Table S2 in the Supplementary Data) is for African ancestry, while European frequencies are ∼0.17 and Asian 
∼0.09. APOE variants are associated with autosomal dominant and multifactorial inheritance of type 3 hyper-
lipoproteinemia. Understanding this genetic disease has been key to identifying the role of APOE in removal 
SNP BP A1 OR SE L95 U95 STAT P
(A)
rs11912237 51060049 A 2.67 0.27 1.58 4.52 3.67 2.43E-04
rs8142033 51062832 A 2.67 0.27 1.58 4.52 3.67 2.43E-04
rs6151429 51063477 G 2.67 0.27 1.58 4.52 3.67 2.43E-04
rs2071421 51064416 G 2.73 0.27 1.62 4.60 3.79 1.54E-04
rs6151419 51064915 A 2.23 0.26 1.35 3.68 3.14 1.72E-03
rs762668 51066990 A 2.52 0.27 1.49 4.27 3.44 5.92E-04
(B)
BP Original P
P after conditioning on
rs6151429 rs2071421 rs6151419
rs6151429 51063477 2.43E-04 1 1 0.05
rs2071421 51064416 1.54E-04 1 1 0.03
rs6151419 51064915 1.72E-03 0.96 0.74 1
rs762668 51066990 5.92E-04 0.84 0.80 0.10
Table 3. Logistic regression analysis of association between ARSA SNPs and T2D. Analysis performed in 
PLINK using an additive model with 10 principal components of variation from the original GWAS analysis8 
used as covariates. Summary data for the top SNP under dominant and recessive models is provided in the text. 
SNP = variant analysed; BP = bp location Build 36; A1 is associated allele; OR = odds ratio; SE = standard error; 
L95 and U95 = lower and upper 95% confidence intervals; STAT = test statistic; P = P-values. (A) are results for 
single SNP association analyses; (B) are results after conditioning on each SNP, as indicated.
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very low density lipoprotein and chylomicrons28. ApoE4 is associated with atherosclerosis29, Alzheimer’s dis-
ease30 and impaired cognitive performance31. A second ClinVar functional variant at high frequency in our study 
was ATP6V0A4 rs3807153 (c.1739T > C; p.Met580Thr; frequency 0.264) which is associated with distal renal 
tubular acidosis32. Again, the high Max-all frequency (0.213; Table S2 in the Supplementary Data) is represent-
ative of African ethnicities, while Europeans (0.01–0.02) and Asians (0.05–0.06) have low frequencies. Using 
CADD scaled scores to identify putative functional variants unique to, or at high frequency, in this Australian 
Aboriginal population showed enrichment for genes (DPH3, DRD2, LIF, OSM, RHBDF2) contributing to negative 
Figure 2. Relationship between ARSA rs6151429 genotypes and QT measures of HTN (DBP and SBP) or renal 
function (ACR and eGFR) in the study population. (A) to (D) show Box and Whiskers Tukey plots for genotype 
by QTs for adult WES participants; (E) to (H) show results for adult WES participants stratified by T2D status.
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regulation of adiponectin secretion. Adiponectin is an adipocyte-derived plasma protein with insulin-sensitizing, 
anti-atherosclerotic and anti-diabetic properties33,34. Adiponectin secretion from omental cells is high, sensitive 
to insulin, and negatively correlated with BMI33. Serum adiponectin is higher in nondiabetics with renal insuffi-
ciency than without34, and has been proposed as a biomarker of CVD35. Larger well-powered studies are required 
to determine the broader impact of these CADD and ClinVar functional variants on CVD and CRD/ESRD in 
Aboriginal Australians.
We noted that ARSA-PD variants are common in this Australian Aboriginal population. Numerous deleteri-
ous protein coding ARSA gene variants are associated with metachromatic leukodystrophy (MLD), a rare lysoso-
mal storage disorder36. Although ARSA-PD variants are not associated with MLD per se, PD variants occurring 
Figure 3. Relationship between ARSA rs6151429 genotypes and QT (DBP and SBP) measures of HTN in the 
GWAS population. (A) and (B) show DBP and SBP by age for all individuals contributing to the GWAS; dotted 
lines indicate clinical cut-offs for HTN. (C) and (D) show Box and Whiskers Tukey plots for genotype by DBP 
and SBP, respectively; (E) and (F) show results stratified by T2D status.
www.nature.com/scientificreports/
9ScIeNtIfIc REPoRtS |  (2018) 8:10912  | DOI:10.1038/s41598-018-29279-9
in cis with MLD-causing mutations could exacerbate the MLD phenotype37. Nevertheless, the 3′ regulatory 
c.*96 A > G (rs6151429) ARSA-PD variant, which severely reduces a 2.1-kilobase mRNA species to give ARSA 
enzyme levels ∼10% of normal, is commonly observed in healthy individuals25. The associated c.1055 A > G (p. 
Asn352Ser; rs2071421; traditionally known as p.Asn350Ser) variant causes the loss of an N-linked glycosylation 
site, affecting transport to the lysosome. Although c.1055 A > G does not itself reduce enzyme activity38, the 
combined effect of the polyadenylation defect and aberrant lysosomal targeting reduces ARSA activity to ∼8% of 
normal39. Similarly, the ARSA missense variant c.511 G > A (p.Asp171Asn; rs74315466) found at high frequency 
in our study, which is reported to lie within a second N-glycosylation site19, may also compromise lysosomal 
Figure 4. Relationship between ARSA rs6151429 genotypes and QT (ACR and eGFR) for renal function in 
the GWAS population. (A) and (B) show ACR and eGFR by age for all individuals contributing to the GWAS; 
dotted lines indicate clinical cut-offs for renal function as annotated. (C) and (D) show Box and Whiskers Tukey 
plots for genotype by ACR and eGFR, respectively; (E) and (F) show results stratified by T2D status.
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targeting to affect ARSA activity and the ARSA-PD phenotype. However, since it also occurs in cis with the other 
PD variants, we cannot draw conclusions about its possible direct contribution to phenotype in this study.
Arylsulfatase A catalyses the degradation of sulfatides, a subgroup of glycosphingolipids highly expressed in 
neural tissue but also found in pancreatic islets of Langerhans where they preserve insulin crystals and monomer-
ize insulin for secretion from beta cells40. An explanation for their role in diabetes22 and the association between 
ARSA-PD variants and T2D observed here could be this direct effect on insulin secretion. Indeed, treatment 
with sulfatides in animal models of T2D enhances glucose-stimulated insulin secretion and improves first-phase 
insulin response41. However, sulfatides are found in many tissues, including kidney42, and serum sulfatides are a 
marker of kidney function43 and a biomarker for CVD particularly in ESRD24. Sulfatides accumulate in high con-
centrations in distal convoluted tubules and collecting ducts of the renal medulla in Arsa knockout mice44, where 
they play a role in urinary acidification and acid-base homeostasis42. It was of interest, therefore, that ARSA-PD 
variants were more strongly associated with QT for CVD/HTN and CRD/ESRD in non-diabetic individuals in 
our study, suggesting direct effects on renal disease and associated cardiovascular dysfunction.
Overall our results highlight associations between ARSA-PD variants and traits associated with CVD, CRD/
ESRD and T2D in Aboriginal Australians. While this likely relates to multiple pleiotropic effects of sulfatides on 
metabolic functions, this work highlights sulfatides as a possible avenue for therapeutic intervention in CVD, 
CRD/ESRD and T2D. More broadly, the use of WES to identify functional ClinVar variants provides important 
baseline information for diagnosis of rare diseases in Aboriginal Australians15, while also demonstrating high 
frequencies for specific functional variants associated with more complex metabolic disease pathways.
Methods
Study Population. As reported8, family-based recruitment was from an Australian Aboriginal community 
of Martu ancestry45 from Western Australia. A memorandum of understanding with the community included 
permission for access to clinical records (e.g. QT and clinical phenotype data, as below) held in a Communicare 
database at the local Aboriginal Health Service. Ethical approval was obtained from, and all protocols approved 
by, the Western Australian Aboriginal Health Ethics Committee (WAAHEC; Reference 227 12/12). The study was 
carried out in accordance with the Declaration of Helsinki Principles, and each participant, or the parent/guard-
ian of individuals <18 years old, signed informed consent forms to participate in the study and provide a DNA 
sample. DNA was prepared from saliva samples collected into Oragene tubes (DNA Genotek, Ontario, Canada) 
from 405 consenting family members. All procedures were also carried out in accordance with established insti-
tutional standard operating procedures for working with human samples. Following feedback to the community, 
permission to publish was provided by the Board of the local Aboriginal Health Service, which comprised elders 
representing the extended families residing in the area.
Genotype data and WES. Post-QC genotype data were available8 for 402 individuals typed on the Illumina 
2.5 M Duo Beadchip. These individuals belonged to inter-related extended pedigrees, as depicted in the radial 
plot which shows hierarchical clustering of estimated pairwise identity-by-descent allele-sharing (Supplementary 
Fig. S3). Principal component (PC) analysis8 demonstrated a degree of introgression of predominantly Caucasian 
origin, with a tight cluster of 195 individuals of pure Martu ancestry across all age groups. Phased haplotypes for 
arylsulphatase A (ARSA) single nucleotide polymorphisms (SNPs) were generated using PLINK46. Association 
analyses were performed in PLINK46 on single SNP or phased haplotype data for 89 cases and 109 controls ≥ 20 
years of age using logistic regression under an additive model with 10 PCs as covariates. Single marker association 
analyses in PLINK aligned closely with results of linear mixed models used in the original genome-wide asso-
ciation analyses8 to take account of both family relationships and genetic substructure. WES data were available 
for 72 individuals (35 pure Martu), for which details of sequence and variant analysis are reported elsewhere16. 
Supplementary Table S5 provides basic demographic data (age, sex; T2D status) for the 391 post-QC individuals 
used in the Illumina 2.5 M Duo Beadchip analyses8, and for the 72 individuals (48 adults aged 52.7 ± 16.3 repre-
senting extremes of renal disease, as defined by estimated glomerular filtration rate (eGFR), with/without T2D; 
24 minors 12.6 ± 7.7 years included for rare variant discovery) with WES16.
Quantitative and phenotypic traits. Renal disease is monitored in the community by regular meas-
urements of albumin:creatinine ratios (ACR; albumin concentration in milligrams/creatinine concentration 
in grams), estimated glomerular filtration rates (eGFR) based on serum creatinine measurements, and HTN 
based on blood pressure measurements. Data for diastolic (DBP) and systolic (SBP) blood pressure (mm Hg), 
ACR, and calculated eGFR data were extracted from the Communicare database. Clinical cut-offs for HTN were 
SBP ≥ 140 mm Hg and DBP ≥ 90 mm Hg; for renal function normal (eGFR > 60), moderate (eGFR 30–59), severe 
(eGFR 15–28), and kidney failure (eGFR < 15); and for ACR as normal (ACR < 30), moderately increased (30–
300), severely increased (ACR > 300). Diabetes/pre-diabetes was monitored using HbA1c, with normal (≤6%, 
equivalent to 42.1 mmol/mol or 7.0 mmol/L); pre-diabetic 6–6.4%; diabetic (≥6.5%). BMI was measured as 
weight (kg)/height (m2).
Defining pathogenic variants. We used two approaches to identify putative pathogenic variants in WES 
data. Firstly, all called variants were compared with functional disease-associated variants in ClinVar14. ClinVar 
uses the five clinical significance categories recommended by the American College of Medical Genetics and 
Genomics47 (benign, likely benign, uncertain significance, likely pathogenic and pathogenic). We restricted our 
comparison to the “pathogenic” or “likely pathogenic” (>90% likelihood of being pathogenic) categories, cri-
teria for which are outlined elsewhere47. Frequencies for the disease-causing alleles (as defined in ClinVar) of 
these variants in our study were compared with the maximum frequency (designated Max-all) reported in either 
the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project (ESP)48, the 1000 Genomes 
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Project49, the Exome Aggregation Consortium (ExAC)50 or the Genome Aggregation Database (gnomAD)50 
databases using GEMINI51. In reporting ClinVar variants we have included all variants (Table S1) designated as 
pathogenic, likely pathogenic, or a risk factor in at least one study. These variants ranged from deleterious variants 
of high burden that have previously been recorded as pathogenic for rare genetic disorders, to those contributing 
to quantitative and/or more complex phenotypes such as the cardiovascular and renal disease phenotypes of 
specific interest to this study. Secondly, we assigned raw and scaled Combined Annotation Dependent Depletion 
(CADD)17 values to all variants called in the WES data and filtered for genes carrying potential deleterious var-
iants. CADD uses 63 different annotations for its combined score17. To provide a “normalized” and externally 
comparable unit, the raw CADD scores for all ~8.6 billion single nucleotide variants (SNVs) of the GRCh37/
hg19 reference have been ranked and “PHRED-scaled” such that reference genome SNVs at the 10th-% of CADD 
scores are assigned to CADD-10, top 1% to CADD-20, top 0.1% to CADD-30, etc17. Although CADD scores cor-
relate with annotations of functionality and pathogenicity17, there is no hard cut-off for deleteriousness to identify 
potentially pathogenic variants. The authors of CADD suggest a cut-off between 10 and 20 for scaled CADD 
scores, possibly at 15 which is the median value for all possible canonical splice site changes and non-synonymous 
variants17. We ranked scaled CADD values internal to our study to determine cut-offs that defined the top 1%, 
5% and 10% of deleteriousness, and again compared study-specific putative deleterious allele frequencies with 
Max-all.
Gene-set enrichment analysis. In addition to manual inspection of genes carrying putative pathogenic or 
deleterious alleles, we used the gene-set enrichment tool Enrichr18 to analyse gene lists for evidence of enrichment 
of pathogenic/deleterious variants in multiple genes in pathways influencing the phenotypes of interest. Canonical 
pathways and gene network analyses based on gene lists were also analysed using QIAGEN’s Ingenuity Pathway 
Analysis (IPA; QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis)52. 
IPA utilises the Ingenuity Knowledge Base, an extensive database comprising biological pathways and func-
tional annotations derived from the interactions between genes, proteins, complexes, drugs, tissues and disease. 
Benjamini-Hochberg (BH) correction was applied and −log PBH-adjusted = 1.3 (PBH-adjusted = 0.05) taken as the 
threshold to report results of pathway analyses. Networks were constructed in IPA using the “Connect” option 
under the “Build” functionality.
Statistical analysis of QT by genotype data. Differences in QT responses between ARSA rs6151429 
genotypes were evaluated using parametric unpaired t-tests with Welch’s correction where between group vari-
ances were not different, and non-parametric Mann-Whitney tests where variances were unequal (ACR response 
data only). For comparison across 4 groups, ordinary one-way analysis of variance (ANOVA) with multiple com-
parisons and correction for multiple testing were employed, or Kruskal-Wallis tests with multiple comparisons 
(ACR response data only). Analyses were performed in GraphPad Prism 7.00.
Availability of Data. Chip-based genotype8 and WES16 data are available through the European 
Genome-Phenome Archive (https://www.ebi.ac.uk/ega/dataproviders/EGAO00000000341) by application to 
study-specific data access committee.
Ethical approval and informed consent. Ethical approval was obtained from, and all protocols approved 
by, the Western Australian Aboriginal Health Ethics Committee (WAAHEC; Reference 227 12/12). The study 
was carried out in accordance with the Declaration of Helsinki Principles, and each participant, or the parent/
guardian of individuals <18 years old, signed informed consent forms to participate in the study and provide a 
DNA sample.
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